Data obtained in the past year underscored the benefit of a triplet regimen comprising bortezomib, lenalidomide, and dexamethasone for patients with newly-diagnosed multiple myeloma, and have provided high-level evidence supporting the safety of adding daratumumab to standard-of-care doublets for those with relapsed and/or refractory disease. As a result, achieving minimal residual disease-negativity at any stage of myeloma is now a realistic possibility.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Durie, B. G. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet http://dx.doi.org/10.1016/S0140-6736(16)31594-X (2016).
Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 754–766 (2016).
Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375, 1319–1331 (2016).
Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328–e346 (2016).
Paiva, B., van Dongen, J. J. & Orfao, A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 125, 3059–3068 (2015).
Rajkumar, S. V. & Harousseau, J. L. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 128, 2757–2764 (2016).
Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906–917 (2014).
Rajkumar, S. V. & Kyle, R. A. Progress in myeloma — a monoclonal breakthrough. N. Engl. J. Med. 375, 1390–1392 (2016).
Lonial, S. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387, 1551–1560 (2016).
Moreau, P. & Rajkumar, S. V. Multiple myeloma — translation of trial results into reality. Lancet 388, 111–113 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.K. has received research funding from Amgen, Celgene, and Takeda. S.V.R. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Kapoor, P., Rajkumar, S. Fresh perspectives on treatment and moments of clarity. Nat Rev Clin Oncol 14, 73–74 (2017). https://doi.org/10.1038/nrclinonc.2016.221
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.221
This article is cited by
-
MAIA under the microscope — bringing trial design into focus
Nature Reviews Clinical Oncology (2019)